Dynamic actin remodelling processes at the leading edge of migrating tumour cells are concerted events controlled by a fine-tuned temporal and spatial interplay of kinases and phosphatases. Actin severing is regulated by actin depolymerizing factor (ADF)/cofilin, which regulates stimulus-induced lamellipodia protrusion and directed cell motility. Cofilin is activated by dephosphorylation through phosphatases of the slingshot (SSH) family. SSH activity is strongly increased by its binding to filamentous actin (F-actin); however, other upstream regulators remain unknown. Here we show that in response to RhoA activation, protein kinase D1 (PKD1) phosphorylates the SSH enzyme SSH1L at a serine residue located in its actin-binding motif. This generates a 14-3-3-binding motif and blocks the localization of SSH1L to F-actin-rich structures in the lamellipodium by sequestering it in the cytoplasm. Consequently, expression of constitutively active PKD1 in invasive tumour cells enhanced the phosphorylation of cofilin and effectively blocked the formation of free actin-filament barbed ends and directed cell migration.
. The concerted regulation of these events is mediated by a complex temporal and spatial interplay of Rho GTPases, kinases and phosphatases.
A key regulator of polarized cell motility is the F-actin depolymerization and severing factor ADF/cofilin (cofilin) 3, 4 . By severing actin filaments, cofilin increases free barbed ends, which are the preferred substrate for dendritic nucleation by the Arp2/3 complex 3 . Cofilin is highly expressed in multiple cancers, including pancreatic cancer and invasive breast cancer 5, 6 . The net effect of the regulation of cofilin activity by signalling cascades mediates whether or not a tumour cell migrates 6, 7 . The activity of cofilin is regulated mainly by phosphorylation and dephosphorylation events, which allow rapid regulation of the enzyme in different regions of the migrating tumour cell 7, 8 . Phosphorylation of cofilin at serine residue 3 (S3), which is mediated by the LIM kinases (LIMK; Lin-11/Isl-1/Mec-3 kinases) LIMK1 or LIMK2 (refs 1, 9) and by TESK (testicular protein kinases) 10, 11 , leads to a loss of actin binding and severing activities and subsequently results in decreased directed cell motility 12 .
The rapid actin-remodelling events at the progressing leading edge of migrating cells require a rapid modulation of cofilin activity 6 . The dephosphorylation of S3 by slingshot (SSH) phosphatases reactivates cofilin 13, 14 . The regulation of slingshots is not well understood, although recently a potential regulation by the phosphatidylinositol-3-OH kinase pathway was implicated 15 . Further, the SSH member SSH1L is regulated by association with filamentous actin, which increases its phosphatase activity 13 . The relocalization of SSH1 at the leading edge of cells is controlled by the phosphorylation-dependent recruitment of 14-3-3 proteins, but the functional consequences are not well defined 13 . PKD1 is a serine/threonine kinase that until now has not been implicated in the regulation of cofilin activity and actin remodelling at the lamellipodium of migrating tumour cells. Depending on its subcellular localization, PKD1 regulates a variety of cellular functions (reviewed in ref. 7) , including membrane receptor signalling 16 , transport processes at the Golgi 17, 18 , protection from oxidative stress at the mitochondria 19 and transcriptional regulation in the nucleus 20 . Recent studies suggest an involvement of PKD1 in the regulation of cell shape, motility and adhesion [21] [22] [23] . However, conclusive molecular mechanisms linking PKD1 to cytoskeletal reorganization and also to mechanisms affecting cell motility have remained elusive.
Here we describe the localized phosphorylation of substrates that regulate actin organization as a potential mechanism by which PKD1 exerts its effects on cell motility. Specifically, we identify SSH1L as a substrate whose phosphorylation by PKD1 mediates relocalization and inhibition, which translates to altered cofilin activity, actin reorganization and decreased directed cell motility. (GFP-PKD1) and F-actin (rhodamine-phalloidin) using confocal microscopy. Nuclei were stained with DAPI. (b) PKD1 and F-actin are in proximity to facilitate Förster energy transfer. HeLa cells were transfected with GFPtagged PKD1 and stained for F-actin (rhodamine-phalloidin). A time-bleach image series was acquired with a Zeiss LSM 510META confocal microscope. Four pre-bleach and post-bleach images of donor (GFP-PKD1) and acceptor (rhodamine-phalloidin) were recorded. The acceptor was photobleached with a 543-nm laser at 100% transmission. The donor was excited at 488 nm with META-Detector Channels 490-543 for detection, and the acceptor was excited at 543 nm with detection channels 560-635. The first pre-bleach and post-bleach images of the series for donor and acceptor are shown. For better visualization of the donor fluorescence intensity, a Rainbow2 lookup table (LUT) was applied to the images. The bleach region of interest (ROI) is shown below the % FRET image. (c) Immunofluorescence analysis of HeLa cells stained for endogenous SSH1L and F-actin (rhodamine-phalloidin), using confocal microscopy. Nuclei were stained with DAPI. (d) PKD1, SSH1L and F-actin co-localize at the edge of lamellipodia. HeLa cells were transfected with GFP-PKD1. Samples were stained with an anti-SSH1L antibody directly labelled with Alexa Fluor 350 dye and with rhodaminephalloidin. (e) PKD1 and SSH1L-Myc are in proximity to facilitate Förster energy transfer. HeLa cells were transfected with GFP-PKD1 and Myc-SSH1L. SSH1L was indirectly labelled with anti-Myc and Alexa Fluor 568 antibodies. A time-bleach image series was acquired. Three pre-bleach and three post-bleach images of donor (GFP-PKD1) and acceptor (Alexa Fluor 568) were recorded. The acceptor was photobleached with the 594 nm laser to decrease donor bleaching artefacts at 100% transmission with a large number of iterations. FRET images were acquired and revealed as described above. Scale bars, 10 µm.
PKD1 regulates SSH1L by phosphorylation at S978
We next investigated whether slingshot is a substrate for PKD1. To test this we used an antibody specifically designed to recognize PKD substrates (antipMotif), which has previously been characterized in detail 25 . We detected enhanced phosphorylation of SSH1L when co-expressed with active PKD1, and decreased phosphorylation when co-expressed with kinase-inactive PKD1, indicating that PKD1 mediates the phosphorylation of SSH1L in vivo (Fig. 2a) . We also used reverse genetics in which we knocked down PKD with specific RNA-mediated interference (RNAi). To enhance PKD1 activity, cells were stimulated with hydrogen peroxide (H 2 O 2 ), which is a strong inducer of PKD1 activation [26] [27] [28] . A knockdown of PKD1 decreased the H 2 O 2 -mediated phosphorylation of SSH1L in comparison with the RNAi control, indicating that SSH1L is indeed a substrate of PKD1 (Fig. 2b) .
By analysing the secondary structure of SSH1L for motifs that correspond to the optimal PKD1 consensus motif 29 we identified two putative phosphorylation sites (S937 and S978) (Fig. 2c) . To analyse whether PKD1 directly phosphorylates SSH1L at these sites, we performed in vitro kinase assays with purified, active PKD1 and bacterially expressed, purified glutathione S-transferase (GST)-tagged SSH1L encompassing the potential PKD1 phosphorylation sites as well as GST-SSH1L serine-to-alanine mutants of these PKD endogenous Blot: anti-pMotif Input controls:
Input controls: SSH1L was immunoprecipitated (anti-HA) and samples were analysed with the anti-pMotif PKD-substrate antibody. Blots were re-probed for SSH1L expression and control blots were probed with anti-actin (loading control) or anti-PKD1 (to show effective knockdown; numbers show knockdown of PKD1 relative to control). (c) The PKD1 consensus motif indicates preference for serines with an arginine at −3 and leucine at −5 relative to the phosphorylated serine. Both serines, S937 and S978, in the serine-rich region of SSH1L fulfil the criteria of ideal phosphorylation consensus sequences. Also shown is the phosphorylation sequence of the known PKD1 substrate Hsp27. (d) Purified GST-fusion proteins of SSH1L encompassing the putative PKD1 phosphorylation sites S937 and S978, as well as fusion proteins of SSH1L.S937A, SSH1L.S978A and SSH1L. S937A/S978A mutants, were subjected to a PKD1 kinase assay. Substrate phosphorylation was detected with the anti-pMotif PKD-substrate antibody. Purified GST alone or GST-Hsp27 served as negative or positive controls. Control blots show substrate loading (anti-GST) and PKD1 (anti-PKD1). (e) Purified GST (control) and GST-SSH1L were subjected to an in vitro kinase reaction with purified, active PKD1. Western blots of resolved proteins were probed with anti-pS978-SSH1L. Control blots show substrate loading (anti-GST) and PKD1 (anti-PKD1). (f) HeLa cells were co-transfected with Myctagged SSH1L or SSH1L.S978A and vector or constitutively active PKD1 (PKD1.CA). SSH1L was immunoprecipitated (anti-Myc) and analysed for phosphorylation at S978 (anti-pS978-SSH1L). Blots were re-probed for SSH1L expression (anti-SSH1L) and control blots were probed for PKD1 (anti-PKD1). Uncropped images of a, d and f are shown in Supplementary  Information, Fig. S6 .
residues (Fig. 2d) . Our in vitro kinase assays suggested that PKD1 directly phosphorylates SSH1L at S978 but not at S937. After this initial mapping we confirmed the phosphorylation of S978 by PKD1 in vitro with a phosphosite-specific antibody directed against phospho-S978-SSH1L (Fig. 2e) 
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. The phosphorylation of S978 in vivo was confirmed by co-expression of active PKD1 with wild-type SSH1L or a SSH1L.S978A mutant (Fig. 2f) . The S978A mutation of SSH1L abrogated the phosphorylation detected with the phospho-S978-SSH1L antibody, demonstrating both the specificity of the phospho-specific antibody used and that S978 is indeed phosphorylated by PKD1 in vivo.
PKD1 regulates SSH1L downstream of RhoA
The Rho GTPase RhoA and slingshot both have been implicated in the regulation of directed cell migration 30 . Further, PKD1 is activated downstream of RhoA 31, 32 , but not of RhoB or RhoC ( Supplementary Information, Fig. S2a ). The expression of active RhoA and subsequent analysis of overexpressed SSH1L with the phospho-S978-SSH1L antibody revealed a RhoA-mediated regulation of the phosphorylation at this site (Fig. 3a) . Next, we analysed whether RhoA-mediated activation of PKD1 regulates the phosphorylation of endogenous SSH1L at S978. Constitutively active RhoA (RhoA.CA) clearly enhanced the phosphorylation of SSH1L at S978; this was decreased when cells were treated with the Rho inhibitor C3 ( Fig. 3b ; Supplementary  Information, Fig. S2b ). Similar results were obtained when SSH1L was overexpressed ( Supplementary Information, Fig. S2c ). Treatment of cells with C3 also released PKD1 from the F-actin structures at the leading edge ( Supplementary Information, Fig. S2c ). To directly link RhoA-mediated phosphorylation of SSH1L to PKD1, we expressed a kinase-dead PKD1 or knocked-down PKD in cells and tested their responsiveness to active RhoA, using SSH1L phosphorylation as readout. We found that both a loss of PKD1 kinase activity and a knockdown of PKD blocked RhoA-mediated phosphorylation of SSH1L at S978 ( Fig. 3c, d ; Supplementary Information, Fig. S2d, e) . This suggests that SSH1L is a PKD1 substrate downstream of active RhoA.
Active PKD1 regulates dissociation of SSH1L from the actin cytoskeleton Next we investigated the consequences of PKD1-mediated phosphorylation of SSH1L at S978. We co-expressed active PKD1 (PKD1.CA) with wild-type SSH1L or its S978A or S937A mutants to investigate their subcellular localization in relation to F-actin. In the absence of active PKD1, wild-type SSH1L and the mutants strongly co-localized with F-actin-rich structures at the periphery of the cell (Supplementary Information, Figs S2a and S4a). However, after expression of active PKD1, SSH1L and the SSH1L. S738A mutant displayed mostly cytoplasmic staining (Fig. 4b, d ). In contrast, the SSH1L.S978A mutant was still localized at F-actin structures at the cell periphery (Fig. 4c ). The expression of kinase-inactive PKD1 (PKD1.KD) did not lead to a redistribution of wild-type SSH1L, underlining the importance of PKD1 kinase activity for this regulation (Fig. 4e) . We confirmed the immunofluorescence data with a biochemical approach, by analysing the F-actin-containing and cytosolic fractions of cells. In control cells SSH1L was localized mainly in the F-actin fraction, whereas in the presence of active PKD1, SSH1L was increasingly found in the cytosolic fraction ( Fig. 4f) . Further, active PKD1 also increased the abundance of an SSH1L.S937A mutant in the cytosolic fraction, whereas an SSH1L.S978A mutant, which is not targeted by PKD1, remained almost exclusively in the F-actin fraction (Fig. 4f ). Taken together, these results show that PKD1, independently of its kinase activity, is localized at peripheral F-actin structures such as membrane ruffles or lamellipodia. However, the localization of SSH1L at these structures is heavily dependent on its phosphorylation at S978, which is mediated by PKD1. 
PKD1-mediated phosphorylation of SSH1L facilitates binding of 14-3-3
We next sought to identify the cellular mechanisms of how PKD1-mediated phosphorylation regulates SSH1L localization on a molecular level. It has previously been suggested 13 that both S937 and S978 form the core motif of a binding site for 14-3-3β or 14-3-3ζ. Further, a F-actin binding motif (L-K-R) has been described 24 within the L-K-R-S-H-S 978 phosphorylation motif surrounding S978 of SSH1L. We therefore proposed that PKD1-mediated phosphorylation of SSH1L at S978 leads to 14-3-3 binding and abrogates F-actin binding of this site, ultimately resulting in altered subcellular localization of SSH1L. Merge Control 14-3-3ζ
Figure 5
Phosphorylation of SSH1L at S978 controls its association with 14-3-3 proteins. (a) HeLa cells were transfected with Myc-SSH1L and vector, constitutively active PKD1 (PKD1.CA) or kinase-dead PKD1 (PKD1. KD). Where indicated, cells were stimulated with H 2 O 2 (10 mM, 10 min). SSH1L was immunoprecipitated (anti-Myc) and samples were stained for phosphorylation at S978 (anti-pS978-SSH1L) and re-probed for total SSH1L (anti-SSH1L). Co-precipitation of 14-3-3 was detected with an anti-14-3-3β antibody. (b) HeLa cells were transfected with control or PKD-RNAi. On the next day, cells were transfected with Myc-SSH1L. After 48 h, cells were stimulated with H 2 O 2 (10 mM, 10 min) as indicated. SSH1L was immunoprecipitated (anti-Myc) and samples were stained for phosphorylation at S978 (anti-pS978-SSH1L) and re-probed for SSH1L (anti-SSH1L). Co-precipitation of 14-3-3 was detected with an anti-14-3-3β antibody. (c) HeLa cells were transfected with RNAi control or PKD-RNAi. Next day, cells were transfected with vector or constitutively active RhoA (RhoA.CA). Endogenous SSH1L was immunoprecipitated (anti-SSH1L) and analysed for co-immunopecipitation of 14-3-3β (anti-14-3-3β). As control, samples were also stained for SSH1L phosphorylation at S978 (anti-pMotif) and equal loading (anti-actin). (d) HeLa cells were co-transfected with Myc-tagged SSH1L or SSH1L.S978A and vector or constitutively active PKD1 (PKD1.CA). SSH1L was immunoprecipitated (anti-Myc) and analysed for co-immunoprecipitation of 14-3-3 (anti-14-3-3β). As control, samples were also stained for SSH1L phosphorylation at S978 (anti-pS978-SSH1L) or equal loading (anti-actin). (e) HeLa cells were transfected with Myc-tagged SSH1L or SSH1L.S978A and HA-14-3-3ζ. 14-3-3ζ was stained with an anti-HA (rat) antibody followed by detection with anti-rat Alexa Fluor 488. SSH1L was detected with anti-Myc and Alexa Fluor 568 antibodies. F-actin was stained with Alexa Fluor 633-phalloidin and nuclei were stained with DAPI. E1-E4: controls transfected with SSH1L and co-stained for F-actin. E5-E8: cells transfected with SSH1L and 14-3-3ζ, and co-stained for F-actin. E9-E12: cells transfected with SSH1L.S978A and co-stained for F-actin. E13-E16: cells transfected with SSH1L.S978A and 14-3-3ζ, and co-stained for F-actin. Images show single confocal sections. The scale bar represents 10 µm. Uncropped images of c and d are shown in Supplementary  Information, Fig. S6 .
To test this, we analysed whether the binding of SSH1L to 14-3-3 proteins is mediated by PKD1. We expressed a constitutively active PKD1, which enhanced the phosphorylation of SSH1L at S978 and also increased its binding to 14-3-3β (Fig. 5a ). Oxidative stress, which potently activates PKD1, served as a positive control and also led to the binding of 14-3-3β to SSH1L. Expression of kinase-dead PKD1 acted in a dominant-negative manner and suppressed both S978 phosphorylation and binding of 14-3-3β proteins (Fig. 5a) . Similar results were obtained with 14-3-3ζ, suggesting that both 14-3-3 isoforms interact with SSH1L in a PKD1-mediated fashion ( Supplementary Information, Fig. S3b) . Further, depletion of PKD by RNAi decreased both the phosphorylation of SSH1L at S978 and the binding of 14-3-3β in response to the potent PKD1 activator H 2 O 2 or the expression of active RhoA (Fig. 5b, c) . To show that 14-3-3 proteins did indeed bind to SSH1L at the S978 residue, 
IEF-PAGE IEF-PAGE 36.9 ± 12% 8.7 ± 3.2% = 3) . g, h, In migrating cells active PKD1 co-localizes with active SSH1L at F-actin filaments. This allows SSH1L to dephosphorylate cofilin and keep it in an active state. Active cofilin induces actin severing and depolymerization, contributing to directional cell migration. After its activation, PKD1 phosphorylates SSH1L at S978. This mediates 14-3-3 binding and inactivation of SSH1L. LIMK keeps cofilin in a phosphorylated, inactive state, blocking F-actin severing, barbed-end formation and directional cell migration.
we compared PKD1-mediated binding of 14-3-3β proteins with that of wild-type SSH1L and the SSH1L.S978A mutant. The S978A mutation abolished the co-precipitation of 14-3-3β, indicating that the interaction of 14-3-3β with SSH1L is completely dependent on the 14-3-3-binding motif created at the PKD1 phosphorylation site (Fig. 5d) .
We then analysed whether binding to 14-3-3ζ alters the cellular localization of SSH1L. In control-transfected cells, SSH1L or the SSH1L.S978A mutant displayed a broad co-localization with F-actin structures (Fig. 5e , E1-E4 and E9-E12). Cells expressing wild-type SSH1L and 14-3-3ζ showed a strong co-localization of both proteins and a sequestration of SSH1L in the cytoplasm away from F-actin structures (Fig. 5e, E5-E8 , middle row). In contrast, co-expression of SSH1L.S978A with 14-3-3ζ showed no such phenotype, and SSH1L.S978A remained localized at F-actin-rich structures in the cell periphery, whereas 14-3-3ζ was mainly localized in the cytoplasm (Fig. 5e, E13-E18, bottom row) . These data suggest that binding of 14-3-3 proteins to the phosphorylated PKD1 consensus motif at S978 is the most likely mechanism by which the subcellular localization of SSH1L is regulated through PKD1.
PKD1 regulates cofilin phosphorylation
The localization of SSH1L to F-actin enhances SSH1L phosphatase activity towards cofilin 13 . We therefore next determined whether the regulation of SSH1L by PKD1 had an impact on its activity towards cofilin. Cofilin phosphorylation at S3 can be used as a direct measure for cofilin activity, and decreased phosphorylation of this residue is due to increased activity of cofilin phosphatases such as SSH1L 13, 14 . Increased PKD activity, as mimicked with a constitutively active PKD1 mutant, resulted in increased cofilin phosphorylation at S3, and the expression of a kinase-dead PKD1 allele decreased cofilin phosphorylation at this site (Fig. 6a) . We also compared cells depleted of PKD (by using specific RNAi) with cells treated with control RNAi and analysed the cofilin phosphorylation status in response to PKD1 activation by oxidative stress or active RhoA (RhoA.CA). Both oxidative stress and RhoA activation enhanced cofilin phosphorylation at S3, suggesting increased inhibition due to PKD1-mediated signalling events (Fig. 6b, c; Supplementary  Information, Fig. S4c ). Our data show that both activators of PKD1 regulate SSH1L by phosphorylation, in a PKD1-dependent manner. Further, these results suggest that SSH1L, once phosphorylated by PKD1 and sequestered by 14-3-3 proteins, is inactive towards cofilin phosphorylated at S3. Finally, we tested whether the effects on the cofilin S3 phosphorylation signal are indeed due to PKD1-mediated phosphorylation of SSH1L at S978. We coexpressed active PKD1 with wild-type or S978A-mutant SSH1L and analysed cofilin phosphorylation at S3 as a measure of cofilin activity (Fig. 6d) . Both wild-type SSH1L and the SSH1L.S978A mutant decreased the basal phosphorylation levels of cofilin. However, the expression of active PKD1 increased the phosphorylation of wild-type cofilin at S3, whereas there was no increase in phosphorylation in cells expressing SSH1L.S978A. This indicates that the effects of PKD1 on cofilin phosphorylation at S3 are mediated through its phosphorylation of SSH1L at S978.
Finally, we determined whether PKD1 alters endogenous cofilin phosphorylation. To test this we subjected cell lysates of control cells or cells transfected with constitutively active PKD1 to isoelectric focusing (IEF)-PAGE. Active PKD1 increased the levels of phospho-S3-cofilin (Fig. 6e) . A quantitative analysis of the percentage of phospho-cofilin determined from total cofilin suggests that active PKD1 increased endogenous phospho-cofilin levels in HeLa cells from 8.7 ± 3.2% of the total cofilin in untreated cells to 36.9 ± 12%. We also found that endogenous, basal phospho-S3-cofilin levels were decreased when cells were depleted of PKD. Knockdown of PKD decreased phospho-S3-cofilin levels in comparison with control cells, from 9.4 ± 2.7% of the total cofilin in control cells to 2.6 ± 0.6% ( Fig. 6e; errors are s.d.) .
PKD1 inhibits barbed-end formation and directed cell migration
The activity status of the cofilin pathway and the subsequent generation of barbed ends correlate with the ability of cells to migrate towards a chemotactic stimulus 4, 33 . Because PKD1 negatively regulates the SSH1L-mediated dephosphorylation and activation of cofilin, we proposed that this also has an impact on the cells' ability to migrate. To test this we first determined the effect of active PKD1 on the formation of free actin-filament barbed ends. We found that active PKD1 completely blocked the formation of free actin barbed ends, suggesting an important role of PKD1 in blocking cofilin-mediated cell migration ( Fig. 7a;  Supplementary Information, Fig. S5a, b) .
We next analysed wild-type, constitutively active PKD1 or inactive mutants of PKD1 for their effects on directional cell migration in Boyden chamber/transwell chemotaxis assays. Constitutively active PKD1 significantly decreased cell migration in both HeLa and MTLn3 cells ( Fig. 7b; Supplementary Information, Fig. S5c ). Short hairpin RNA (shRNA) directed against PKD1 or the expression of kinase-dead (PKD1.KD) or inactive PKD1 (PKD1.SSAA) mutants increased cell motility ( Fig. 7c; Supplementary Information, Fig. S5d ). In addition to the transwell chemotaxis assays, we performed cell tracking assays in which we compared directed cell migration of MTLn3 cells expressing constitutively active PKD1 or vector control towards NIH-3T3-conditioned medium using µ-Slide chemotaxis (Fig. 7d) . Control cells had an average velocity of 24 µm h −1 and a directionality of 0.21, whereas cells transfected with constitutively active PKD1 had an average velocity of 18 µm h −1 and a directionality of 0.08. These effects on directed cell motility confirmed the results obtained with the transwell chemotaxis assays. PKD1 and mutants had no significant effects on random cell migration ( Supplementary Information, Fig. S5e) , suggesting a specific role of PKD1 in directed cell migration.
We next determined whether PKD1 exerts its inhibitory function on directed cell migration through its activity on SSH1L. The co-expression of active PKD1 with SSH1L significantly decreased directed cell migration in comparison with SSH1L alone. This was rescued by the SSH1L.S978A mutant, which cannot be phosphorylated by PKD1 (Fig. 7e) . Because slingshots directly regulate phospho-cofilin levels, we then determined whether constitutively active PKD1 affects cofilin-mediated cell migration (Fig. 7f) . We found that cell migration was increased in cells expressing wild-type cofilin or a cofilin.S3A mutant, which cannot be regulated by SSH1L and LIMK. The co-expression of active PKD1 inhibited the effects on cell migration mediated by the wild-type cofilin, but did not block effects mediated by the cofilin.S3A mutant (Fig. 7f) . This was most probably due to PKD1-mediated regulation of SSH1L. As a control, a cofilin.S3E mutant mimicking the phosphorylation of this site inhibited cell migration. Taken together, our data identify PKD1 as a key regulator of the SSH1L-cofilin signalling pathway and directed cell migration.
DISCuSSIon
Rapid actin severing and polymerization at the leading edge of migrating or invading tumour cells require a cycling process of ADF/cofilin activation and inactivation 2, 6, 7 , which is mediated by phosphorylation through LIMK and dephosphorylation by slingshot phosphatases 10, 11 . Relatively little is known about the regulation of slingshot, and by demonstrating its phosphorylation by PKD1 we here define a new regulation mechanism for this phosphatase.
Rho GTPases are key regulators of cell migration, and they control many processes of cell adhesion and actin dynamics. Cdc42 and Rac1 have been implicated in regulating the formation of filopodia and lamellipodia, whereas RhoA is important in the inhibition of actin severing at the leading edge 34 . PKD1 is activated downstream of RhoA
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; however, the functions of this activation are not well defined. We found that RhoA-mediated activation of PKD1 leads to the phosphorylation of SSH1L at S978 and the subsequent inhibition of cofilin (Figs 3 and  6 ). Another PKD1 activation pathway, mediated by oxidative stress, also leads to similar SSH1L regulation (Figs 3 and 6) . Activation of PKD1 in response to both stimuli is mediated by novel protein kinase C (nPKC) enzymes, which induce PKD1 activation loop phosphorylation 35 . The activation of both nPKC and PKD1 is dependent on the lipid co-activator diacylglycerol (DAG), which targets these kinases to membrane structures within cells [36] [37] [38] . Cleavage of PtdIns(4,5)P 2 by PLC releases cofilin from its complex with PtdIns(4,5)P 2 at the plasma membrane 39 . This cleavage also generates DAG, which could recruit and activate PKD1 and its upstream kinases. Once activated, PKD1 then phosphorylates its substrate SSH1L, regulating its activity and subcellular localization.
Serine residue 978 is located within a potential actin-binding motif in SSH1L 24 . SSH1L activity is strongly increased after binding to F-actin, resulting in the dephosphorylation and activation of cofilin 13 . We therefore proposed that the phosphorylation of this residue by PKD1 regulates SSH1L-actin interactions and SSH1L activity towards cofilin. The PKD1-mediated phosphorylation of SSH1L at S978 generates a 14-3-3-binding motif (RSXpS), which is a common feature of PKD1 substrates 17 . Our results indicate that 14-3-3 binding allows the sequestration of SSH1L away from filamentous actin (Fig. 5) , resulting in decreased activity towards cofilin at the leading edge.
The activity status of cofilin is directly relayed to the motility of cancer cells 4, 6, 40 . This prompted us to investigate whether PKD1 exerts effects on cofilin-mediated actin remodelling of the dendritic network. The expression of active PKD1 in MTLn3 cells, which are a genuine model system for barbed-end formation 6 , demonstrated that PKD1 induced a global inhibition of actin incorporation ( Fig. 7a; Supplementary Information,  Fig. S5a, b) . Our data suggest the following mechanism: PKD1-mediated SSH1L phosphorylation effectively renders cofilin inactive, thereby failing to generate sufficient barbed ends for actin polymerization and Arp2/3-mediated branching 41 . Similar marked effects on barbed-end formation have been described after overexpression of LIMK 4, 7, 8, 42, 43 . Given that LIMK is also activated downstream of a RhoA-ROCK signalling cascade 30 , it is plausible that both enzymes -LIMK and PKD1 -synergize to facilitate the inactivation of cofilin. It is also possible that PKD1, in addition to regulating SSH1L activity, also activates LIMK. However, in HeLa cells LIMK had only basal activity, and a knockdown of endogenous PKD1 had no significant effects on the activity of endogenous LIMK in control or RhoA-stimulated cells (data not shown).
The inhibition of barbed-end formation by PKD1 directly translated to a decrease in directed cell migration of tumour cells ( Fig. 7b-d ; Supplementary Information, Fig. S5c, d ). This correlates with data obtained with pancreatic adenocarcinoma cell lines, in which the stable overexpression of PKD1 also inhibited cell migration 21 . Directed cell migration in response to a chemotactic stimulus requires cofilin activation at the leading edge. However, it also requires tight regulation or inactivation of cofilin in areas other than the lamellipodium, allowing only controlled and cyclic actin severing at the leading edge 6 . Such global inactivation of cofilin is also mediated by RhoA and is required for prevention of the uncontrolled formation of additional lamellipodia, to ensure directed cell migration 8 . Our data point to a role of PKD1-mediated regulation of SSH1L at the leading edge. We predict that PKD1, depending on its intracellular localization, could have important functions in vivo during other stages of the cofilin cycling process. Our data also suggested clustering of subcellular pools of PKD1 and SSH1L at perinuclear structures (Fig. 1d) , which are most probably parts of the trans-Golgi network (TGN). A Golgi-located pool of PKD1 has been shown to facilitate vesicular transport from the TGN to the plasma membrane 17 . Our observation also indicates a potential function of PKD1/ SSH1L signalling in actin remodelling events at the TGN complex involved in the scission of transport vesicles 18 . In summary, this study links PKD1 to cofilin-induced actin remodelling processes, which are essential for the initiation of polarized cell migration of cancer cells. We show that PKD1 regulates cofilin by phosphorylation of its activator SSH1L at S978, thereby creating a 14-3-3-binding motif. Binding of 14-3-3 to SSH1L results in the release of this phosphatase from F-actin and to its sequestration in the cytoplasm. This translocation inhibits SSH1L activity towards cofilin and blocks barbed-end formation and directed cell migration (Fig. 7g, h ).
METHoDS
Cell lines, antibodies and reagents. HeLa cells were maintained in DMEM with 10% FBS, and MTLn3 cells were maintained in minimal essential medium with 5% FBS. Anti-GST, anti-PKD1 and anti-14-3-3β antibodies were from Santa Cruz; antiMyc was from Zymed; anti-haemagglutinin, anti-Flag (M2) and anti-actin were from Sigma-Aldrich; anti-GFP/YFP (Ab290) was from Abcam; anti-SSH1L was from ECM Biosciences; and anti-pMotif (PKD substrate antibody) and anti-pS3-cofilin were from Cell Signaling Technology. The anti-pS978-SSH1L antibody was described previously 13 . Secondary horseradish peroxidase-linked antibodies were from Roche. Secondary antibodies (donkey anti-rat IgG Alexa Fluor 488, goat anti-mouse Alexa Fluor 488 F(ab´) 2 , goat anti-rabbit Alexa Fluor 488 F(ab´) 2 ; goat anti-mouse Alexa Fluor 568 F(ab´) 2 ) were from Invitrogen. H 2 O 2 was from Fisher Scientific. HeLaMonster (Mirus) and Superfect (Qiagen) were used for transient transfection of HeLa cells, and Lipofectamine 2000 (Invitrogen) was used for MTLn3 cells.
DNA constructs. Expression plasmids including haemagglutinin (HA)-tagged wild-type, PKD1.CA (constitutively active) and PKD1.KD (kinase-dead, K612W mutation) or yellow fluorescent protein (YFP)-tagged wild-type, S3A or S3E cofilin were described previously 19, 28, 35, 44 . The use of PKD-RNAi was described elsewhere 17 . The expression plasmids pUCD2-3×HA-SSH1L, pYFP-C1-SSH1L, pcDNA3.1-SSH1L-Myc-His, pcDNA3.1-SSH1L-Myc-His. S937A, pcDNA3.1-SSH1L-Myc-His.S978A and pcDNA3.1-SSH1L-Myc-His. S937A.S978A were described previously 13 . Mutagenesis to generate YFP-C1-SSH1L.S978A was performed with the QuikChange kit (Stratagene), and 5´-CTGAAGCGCTCACACGCTCTTGCCAAGCTGGGG-3´ and 5´-CCCCAGCTTGGCAAGAGCGTGTGAGCGCTTCAG-3´ as primers. GST-SSH1L fragments (S910-TGA) were generated by PCR with pcDNA3.1-SSH1L and mutants, and 5´-CGCGGATCCAGTTTCTCAAAAGACTTT-3´ and 5´-CGCCTCGAGTCAGCTTTTGCTCATCCA-3´ as primers. Fragments were cloned into pGEX4-T1 by using BamHI/XhoI. GST-Hsp27 was described previously 25 . Flag-tagged cofilin was generated by amplification of human cofilin from a MDA-MB-231 cDNA library with the use of 5´-GCGGGATCCATGGCCTCCGGTGTGGCTGTCTCT-3´ and 5´-CGCCTC-GAGTCATTTGTCATCATCGTCCTTATAGTCCAAAGGCTTGCCCTC-CAGGGAGAT-3´ primers and cloning into pcDNA4/TO (Invitrogen) with BamHI/XhoI. The pCH110 β-galactosidase reporter construct was described previously 28 . The pcDNA3-14-3-3ζ-HA expression plasmid was from M. Yaffe (Massachusetts Institute of Technology).
Immunoblotting, immunoprecipitation and PAGE. Cells were washed twice with ice-cold PBS (140 mM NaCl, 2.7 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , pH 7.2) and lysed with lysis buffer I (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA pH 7.4) plus Protease Inhibitor Cocktail (Sigma-Aldrich) to obtain the cytosolic fraction. Lysates were vortex-mixed and incubated on ice for 30 min. After centrifugation (13,000 r.p.m., 10,000 g, 15 min, 4 °C), pellets were redissolved in lysis buffer II (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 10 mM NaF, 1 mM Na 3 VO 4 , 1% Nonidet P40, 10% glycerol) and boiled to obtain the actin fraction. For other experiments, cells were lysed with lysis buffer II plus Protease Inhibitor Cocktail. Proteins of interest were immunoprecipitated by incubation for 1 h with a specific antibody (2 µg) followed by incubation for 30 min with Protein G-Sepharose (Amersham Biosciences). Immune complexes were washed three times with TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl) and resolved in 20 µl of TBS and 2 × Laemmli buffer. Samples were subjected to SDS-PAGE or IEF-PAGE (precast IEF pH 3-10 gels were from Bio-Rad). After PAGE, proteins were transferred to nitrocellulose membranes and revealed by immunostaining.
In vitro kinase assays. Kinase assays with GST fusion proteins were performed by adding 250 ng of active, purified PKD1 (Upstate) to 2 µg of purified GST-fusion protein in 40 µl of kinase buffer (50 mM Tris pH 7.4, 10 mM MgCl 2 and 2 mM dithiothreitol) supplemented with 100 µM ATP. The kinase reaction (10 min, 20 °C) was stopped by the addition of 2 × Laemmli buffer.
Immunofluorescence microscopy. Cells were plated on glass coverslips. Samples were washed twice with PBS, fixed with 3.5% paraformaldehyde (15 min, 37 °C), washed three times with PBS, permeabilized with 0.1% Triton X-100 in PBS (2 min, room temperature) and blocked with 3% BSA and 0.05% Tween 20 in PBS (30 min, room temperature). Coverslips were incubated with primary antibodies (1:2,000 dilution, 2 h, 20 °C), washed five times with PBS and incubated with secondary antibodies (1:500 dilution, 2 h, room temperature). F-actin was stained with rhodamine-phalloidin (Sigma) or Alexa Fluor 633-phalloidin (Molecular Probes); nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Coverslips were mounted in Fluromount-G (Southern Biotech). Samples were examined with an LSM 510META confocal laser scanning microscope (Zeiss) with a Plan-Apochromat 63×/1.4 numerical aperture Dic oil-immersion objective. DAPI was excited at the 405-nm laser line, Alexa Fluor 350 at 405 nm, Alexa Fluor 488/GFP at 488 nm, rhodamine-phalloidin/ Alexa Fluor 568 at 543 nm and Alexa Fluor 633-phalloidin at 633 nm, in a multi-track configuration, switching tracks after each line (DAPI, BP420-480; Alexa Fluor 488/GFP, BP505-530; rhodamine/Alexa Fluor 568, META channels 550-615; Alexa Fluor 633, META channels 636-711). Images were processed with NIH ImageJ.
Acceptor photobleach FRET. Transfection, plating, fixation and staining of cells and mounting of samples were performed as described above. Samples were examined with an LSM 510META confocal laser scanning microscope. For acceptor photobleach FRET imaging, the Zeiss LSM Software FRETplus Macro in channel mode was used. Gain and offset were adjusted to be within the lower linear range by using intensity range settings. Lasers and detection channels were changed after every FRAME. All settings were adjusted with the FRETplus Macro. Percentage FRET images were calculated with the FRETplus Macro acceptor photobleach analysis module. For presentation purposes, donor and acceptor thresholds for the calculation of percentage FRET images were adjusted to reduce background noise and enhance the signal-to-noise ratio.
Analysis of free actin-filament barbed ends. Cells were transfected and reseeded on an eight-well ibiTreat µ-Slide (Ibidi; Integrated BioDiagnostics). Cells were serum-starved for 16 h. Further treatment was perfomed as described elsewhere 45 . In brief, the medium was removed, cells were washed with prewarmed PBS, then permeabilized and labelled with 0.4 µM Actin-Alexa Fluor594 in permeabilization buffer (20 mM HEPES, 138 mM KCl, 4 mM MgCl 2, 3 mM EGTA, 0.2 mg ml −1 saponin, 1% BSA) plus 1 mM ATP for 30 s at 37 °C. The cells were fixed with 4% paraformaldehyde in PBS (room temperature, 10 min).
Transwell chemotaxis assays. Assays were performed as described previously 46 , with 24-well Transwell filters (Corning) with a pore diameter of 8 µm. In brief, cells were transfected with plasmids of interest and a β-galactosidase marker (pCH110) at a ratio of 3:1. After 24 h, cells were seeded on Transwell filters in DMEM plus 0.1% BSA and induced to migrate towards NIH-3T3-conditioned medium. Cells were fixed with 3.7% formaldehyde in PBS (30 min, room temperature). The inside of the Transwell insert was wiped and filters were washed several times with PBS. Transfected cells on the bottom of the filter were stained for β-galactosidase expression, and positive cells of triplicate filters were counted for each condition. 
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Figure S1 (A) Endogenous PKD1 and F-actin co-localize. HeLa cells were analyzed for co-localization of endogenous PKD1 (α-PKD1, green) with Actin (phalloidin staining, red) using confocal microscopy. Nuclei were stained with DAPI. The overlay shows co-localization of PKD1 with F-actin. The scale bar represents 10 µm. (B) PKD1 and F-actin co-localize independent of PKD1 activity. HeLa cells were transfected with GFP-tagged constitutivelyactive PKD1 (PKD1.CA) or kinase-dead PKD1 (PKD1.KD). Samples were analyzed for co-localization of PKD1with Actin (phalloidin staining, red) using confocal microscopy. Nuclei were stained with DAPI. The overlay shows co-localization of PKD1 with F-actin. The scale bar represents 10 µm. (C) Endogenous SSH1L and F-actin co-localize. HeLa cells were analyzed for co-localization of endogenous SSH1L (α-SSH1L, green) with Actin (phalloidin staining, red) using confocal microscopy. The overlay shows colocalization of SSH1L with F-actin. The scale bar represents 10 µm. .S937A or SSH1L.S978A. Samples were subjected to indirect immunofluorescence analysis. SSH1L was detected using a α-myc antibody, F-actin was stained with Phalliodin and nuclei were stained with DAPI. Samples were analyzed using a Zeiss LSM 510META confocal microscope with a Plan-Apochromat 63x/1.4 Dic oil immersion objective in Multi-Track-configuration. Images shown depict single confocal sections. The scale bar represents 10 µm. B) SSH1L binds to 14-3-3ζ in response to active PKD1. HeLa cells were transfected with YFP-tagged SSH1L, HA-tagged 14-3-3ζ and vector, constitutively-active PKD1 (PKD1.CA), or kinase-dead PKD1 (PKD1.KD) as indicated. SSH1L was immunoprecipitated (α-GFP) and samples were stained for co-immunoprecipitation of 14-3-3ζ using a α-HA antibody. Samples were re-probed for total SSH1L (α-GFP).
Lysates were analyzed for PKD1 (α-PKD1) and 14-3-3ζ expression (α-HA).
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